Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest
Mandate

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

April 12, 2024 M&A Banking and Finance Restructuring and Insolvency

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.

Norstat is one of the leading data collectors for market research and insight in Europe. Norstat serves more than 2,000 market research firms, private and public end-clients, media agencies, publishers, and consultancies across different industries. The company was established in Norway in 1997 and has since grown its geographical presence to include Denmark, Sweden, Finland, Estonia, Latvia, Lithuania, Poland, Germany, the United Kingdom, France, Switzerland, the Netherlands, Austria and Italy.

The transaction is subject to applicable regulatory approvals.

Vinge’s team consisted mainly of Christina Kokko, Johanna Wiberg, Amanda Steen, Robin Fagerström, Filip Magnusson and Saga Meyer Viklund (M&A), Helena Göransson (Banking and Finance), Daniel Wendelsson, David Olander and Alva Chambert (Regulatory) and Ellinore Boström Andersson, Gabriella Balbo and Fanny Askelöf (Transaction Support Specialists).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025